Pushing the limits of targeted therapy in chronic myeloid leukaemia

被引：250

作者：

O'Hare, Thomas ^{[1
]}

Zabriskie, Matthew S. ^{[1
]}

Eiring, Anna M. ^{[1
]}

Deininger, Michael W. ^{[1
]}

机构：

[1] Univ Utah, Div Hematol & Hematol Malignancies, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

来源：

NATURE REVIEWS CANCER | 2012年 / 12卷 / 08期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; KINASE DOMAIN MUTATIONS; DIAGNOSED CHRONIC-PHASE; BCR-ABL1; LYMPHOBLASTIC-LEUKEMIA; COMPLETE MOLECULAR REMISSION; PATIENTS RECEIVING IMATINIB; CHROMOSOME-POSITIVE CELLS; BCR-ABL INHIBITORS; STEM-CELLS; TYROSINE KINASE;

D O I：

10.1038/nrc3317

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.

引用

页码：513 / 526

页数：14

共 167 条

[21] Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease [J].

Chomel, Jean-Claude ;

Bonnet, Marie-Laure ;

Sorel, Nathalie ;

Bertrand, Angelina ;

Meunier, Marie-Claude ;

Fichelson, Serge ;

Melkus, Michael ;

Bennaceur-Griscelli, Annelise ;

Guilhot, Francois ;

Turhan, Ali G. .

BLOOD, 2011, 118 (13) :3657-3660

[22] BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells [J].

Chu, S ;

Holtz, M ;

Gupta, M ;

Bhatia, R .

BLOOD, 2004, 103 (08) :3167-3174

[23] Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment [J].

Chu, Su ;

McDonald, Tinisha ;

Lin, Allen ;

Chakraborty, Sujata ;

Huang, Qin ;

Snyder, David S. ;

Bhatia, Ravi .

BLOOD, 2011, 118 (20) :5565-5572

[24] Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].

Clark, RE ;

Dodi, IA ;

Hill, SC ;

Lill, JR ;

Aubert, G ;

Macintyre, AR ;

Rojas, J ;

Bourdon, A ;

Bonner, PLR ;

Wang, LH ;

Christmas, SE ;

Travers, PJ ;

Creaser, CS ;

Rees, RC ;

Madrigal, JA .

BLOOD, 2001, 98 (10) :2887-2893

[25] Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation [J].

Coluccia, Addolorata Maria Luce ;

Vacca, Angelo ;

Dunach, Mireia ;

Mologni, Luca ;

Redaelli, Sara ;

Bustos, Victor H. ;

Benati, Daniela ;

Pinna, Lorenzo A. ;

Gambacorti-Passerini, Carlo .

EMBO JOURNAL, 2007, 26 (05) :1456-1466

[26] Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction [J].

Copland, Mhairi ;

Hamilton, Ashley ;

EIrick, Lucy J. ;

Baird, Janet W. ;

Allan, Elaine K. ;

Jordanides, Niove ;

Barow, Martin ;

Mountford, Joanne C. ;

Holyoake, Tessa L. .

BLOOD, 2006, 107 (11) :4532-4539

[27]

Corbin A. S., 2008, BLOOD, V112, P190

[28] Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity [J].

Corbin, Amie S. ;

Agarwal, Anupriya ;

Loriaux, Marc ;

Cortes, Jorge ;

Deininger, Michael W. ;

Druker, Brian J. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (01) :396-409

[29] Gastrointestinal stromal tumours: origin and molecular oncology [J].

Corless, Christopher L. ;

Barnett, Christine M. ;

Heinrich, Michael C. .

NATURE REVIEWS CANCER, 2011, 11 (12) :865-878

[30]

Cortes J, 2011, BLOOD, V118, P601

← 1 2 3 4 5 6 7 8 9 10 →